Method of Preventing and Treating COVID-19 Infection

ABSTRACT

A method of preventing COVID-19 infection in an individual, the method comprising the steps of providing an individual that is not infected with COVID-19; administering four antimicrobials to the individual, wherein the antimicrobials comprise: hydroxychloroquine; vitamin C; vitamin D; and zinc; and monitoring the individuals condition over a pre-determined amount of time to determine the individual does not become infected with COVID-19. A method of treating an individual infected with COVID-19, the method comprising the steps of: providing an individual infected with COVID-19; administering five antimicrobials to the individual, wherein the antimicrobials comprise: hydroxychloroquine; azithromycin; vitamin C; vitamin D; and zinc; and monitoring the individuals condition over a pre-determined period of time to determine whether the individual is no longer infected with COVID-19.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Patent ApplicationNo. 62/993,345, titled “Method of Treating and Preventing COVID-19Infection,” filed Mar. 23, 2020, U.S. Provisional Patent Application No.63/022,371, titled “Method of Treating and Preventing COVID-19Infection,” filed May 8, 2020, U.S. Provisional Patent Application No.63/002,494, titled “Method of Using Vitamin C, Vitamin D, Zinc, andOptionally Hydroxychloroquine, to Prevent COVID-19 Infection,” filedMar. 31, 2020, U.S. Provisional Patent Application No. 63/022,368,titled “Method of Using Vitamin C, Vitamin D, Zinc, and OptionallyHydroxychloroquine, to Prevent COVID-19 Infection,” filed May 8, 2020,and U.S. Provisional Patent Application No. 63/001,161, titled “Methodof Using Aerosolized Hydroxychloroquine, Vitamin C, and Zinc to TreatCovid-19 Infection,” filed Mar. 27, 2020, the contents of which areincorporated by reference in their entirety.

BACKGROUND

COVID-19 is a novel betacoronavirus that originated in bats in the cityof Wuhan, China. This disease has rapidly spread to become a worldwidepandemic, as declared by the World Health Organization (WHO). Symptomsof COVID-19, including fever, myalgia, coughing and shortness of breath,may appear from 2 and 14 days after exposure. Approximately 20% ofpatients progress to severe illness, including pneumonia, respiratorydistress, and even death. Cases in the US have increased five-fold overthe last week, alone. The disease is spreading rapidly, and a cure isdesperately needed.

Nucleotide analogues, protease inhibitors and altered cellular bondingdue to pH change will maximize host protection by: optimizing levels ofgamma interferon and reducing the level of pathogenic microbes in theairways, especially in ‘at risk’ patients.

It is known that single anti-viral agents work poorly when used alone inother chronic viral infections such as Hepatitis C or HIV infection.Therefore, the greater the number of anti-viral agents used incombination, the greater the cure rate.

Thus, there is a significant unmet need for preventing and treating thisviral infection. The present invention addresses this need.

SUMMARY

In a first embodiment, the invention herein is directed to my method ofpreventing COVID-19 infection in an individual. The method of preventioncomprises the steps of providing an individual that is not infected withCOVID-19; administering four antimicrobials to the individual, whereinthe antimicrobials comprise: chloroquine or hydroxychloroquine; vitaminC; vitamin D; and zinc; and monitoring the individual's condition over apre-determined amount of time to determine the individual does notbecome infected with COVID-19.

Optionally, the method of prevention comprises administeringhydroxychloroquine in a daily dosage range of 20 mg to 2,000 mg;administering vitamin C in a daily dosage range of 250 mg to 10,000 mg;administering vitamin D in a daily dosage range of 1,000 mg to 100,000mg; and administering zinc in a daily dosage range of 5 mg to 100 mg.

Optionally, the method of prevention comprises administering, on day 1:two doses of 200 mg of hydroxychloroquine; one dose of 3,000 mg ofvitamin C; one dose of 3,000 mg of vitamin D; and one dose of 50 mg ofzinc; and administering on day 2: one dose of 3,000 mg of vitamin C; onedose of 3,000 mg of vitamin D; and one dose of 50 mg of zinc.

The step of administering on day 2 can be performed for as many days asa supervising physician deems necessary.

The antimicrobials can be administered orally in the form of anaerosolized spray.

The two doses of hydroxychloroquine can be administered as a singledaily dose.

In a second embodiment, the invention herein is directed to my method oftreating an individual infected with COVID-19. The method of treatmentcomprises the steps of: providing an individual infected with COVID-19;administering five antimicrobials to the individual, wherein theantimicrobials comprise: chloroquine or hydroxychloroquine;azithromycin; vitamin C; vitamin D; and zinc; and monitoring theindividuals condition over a pre-determined period of time to determinewhether the individual is no longer infected with COVID-19.

Optionally, the method of treatment comprises administeringhydroxychloroquine in daily dosage range of 20 mg to 2,000 mg;administering azithromycin in a daily dosage range of 250 mg to 500 mg;administering vitamin C in a daily dosage range of 250 mg to 10,000 mg;administering vitamin D in a daily dosage range of 1,000 mg to 100,000mg; and administering zinc in a daily dosage range of 5 mg to 100 mg.

Optionally, the method of treatment comprises the steps of:administering, on day 1: two doses of 200 mg of hydroxychloroquine; onedose of 500 mg of azithromycin; one dose of 3,000 mg of vitamin C; onedose of 3,000 mg of vitamin D; and one dose of 50 mg of zinc;administering daily, on days 2 to 5: two doses of 200 mg ofhydroxychloroquine; one dose of 250 mg of azithromycin; one dose of3,000 mg of vitamin C; one dose of 3,000 mg of vitamin D; and one doseof 50 mg of zinc; and administering daily, on days 6 to 10: two doses of200 mg of hydroxychloroquine; one dose of 3,000 mg of vitamin C; onedose of 3,000 mg of vitamin D; and one dose of 50 mg of zinc.

The antimicrobials can be administered orally in the form of anaerosolized spray.

The two doses of hydroxychloroquine can be administered as a singledaily dose.

The method of treatment can further comprise administering daily, ondays 6 to 10, administering one dose of 250 mg of azithromycin.

BRIEF DESCRIPTION OF THE DRAWINGS

Further advantages of the present invention may become apparent to thoseskilled in the art with the benefit of the following detaileddescription of the preferred embodiments and upon reference to theaccompanying drawings in which:

FIG. 1 is a flow chart depicting the steps of a method of preventinginfection of an individual with COVID-19;

FIG. 2 is a flow chart depicting the steps of a method of treating anindividual infected with COVID-19;

FIG. 3A is a graphical representation of whole genome alignment ofSARS-CoV-2 in patient 1 of Example 6;

FIG. 3B is a graphical representation of whole genome alignment ofSARS-CoV-2 in patient 3 of Example 6;

FIG. 3C is a graphical representation of whole genome alignment ofSARS-CoV-2 in patient 4 of Example 6;

FIG. 3D is a graphical representation of whole genome alignment ofSARS-CoV-2 in patient 6 of Example 6;

FIG. 3E is a graphical representation of whole genome alignment ofSARS-CoV-2 in patient 8 of Example 6;

FIG. 3F is a graphical representation of whole genome alignment ofSARS-CoV-2 in patient 10 of Example 6;

FIG. 3G is a graphical representation of whole genome alignment ofSARS-CoV-2 in patient 11 of Example 6; and

FIG. 3H is a graphical representation of whole genome alignment ofSARS-CoV-2 in patient 12 of Example 6.

DETAILED DESCRIPTION

As used herein, the following terms and variations thereof have themeanings given below, unless a different meaning is clearly intended bythe context in which such term is used.

The terms “a,” “an,” and “the” and similar referents used herein are tobe construed to cover both the singular and the plural unless theirusage in context indicates otherwise.

As used in this disclosure, the term “comprise” and variations of theterm, such as “comprising” and “comprises,” are not intended to excludeother additives, components, integers ingredients or steps.

Referring now to the drawings, wherein like reference numerals designateidentical or corresponding features throughout the several views.Further, described herein are certain non-limiting embodiments of mypipeline filter assembly for pool filtering and maintenance.

The following discussion describes in detail multiple embodiments of theinvention with several variations of those embodiments. This discussionshould not be construed, however, as limiting the invention to thoseparticular embodiments. Practitioners skilled in the art will recognizenumerous other embodiments as well.

In a first embodiment, the present invention is directed to a method ofpreventing COVID-19 infection in an individual. The method involvesadministration of chloroquine or hydroxychloroquine, Vitamin C, VitaminD, and Zinc. Both methods are discussed in greater detail below.

Referring now to FIG. 1, there is shown the method of prevention. Themethod of prevention comprises administering four differentantimicrobials. The four antimicrobials comprise: chloroquine orhydroxychloroquine, vitamin C, vitamin D, and zinc.

Day 1 the individual takes the following, ideal, regimen outlined inTable 1:

TABLE 1 Drug AM Dose PM Dose Hydroxychloroquine  200 mg 200 mg Vitamin C3000 mg — Vitamin D 3000 mg — Zinc  50 mg —

Optionally, the method of prevention can comprise administering on day2: 3,000 mg of vitamin C; 3,000 mg of vitamin D; and 50 mg of zinc.

Hydroxychloroquine is administered only on day 1. The half-life ofhydroxychloroquine is up to 32 days, thus treatment with this drug forone day should be sufficient. However, should the need to prevent theinfection or disease last longer than 32 days, repeat dosing can beconsidered. Accordingly, if necessary, the cycle of day 1 followed byday 2 can be repeated weekly, 2^(nd)-weekly, every 3 weeks, 4 weeks, 5weeks, 6 weeks, 7 weeks, or 8 weeks.

Vitamin C is administered at 3,000 mg per day ongoing. This 3,000 mg canbe broken up into two 1500 mg doses, one taken in the morning and onetaken at night.

Vitamin D is administered at 3,000 mg per day ongoing. This 3,000 mg canbe broken up into two 1500 mg doses, one taken in the morning and onetaken at night.

Zinc is administered at 50 mg per day ongoing. This 50 mg can be brokenup into two 25 mg doses, one taken in the morning and one taken atnight.

Chloroquine or hydroxychloroquine can be administered in a daily dosagerange of 20 mg to 2,000 mg. The above amounts recited in the tables arenot limiting.

Vitamin C can be administered in a daily dosage range of 250 mg to10,000 mg. The above amounts recited in the tables are not limiting.

Vitamin D can be administered in a daily dosage rage of 1,000 mg to100,000 mg. The above amounts recited in the tables are not limiting.

Zinc can be administered in a daily dosage of 5 mg to 100 mg. The amountof Zinc can be reduced to 25 mg per day if gastrointestinal upsetoccurs.

Zinc, Vitamin C and D help in numerous aspects of viral protectionthrough cellular metabolism, including catalytic activity of enzymes,and play roles in immune function, protein synthesis.

The chloroquine or hydroxychloroquine can come in various forms: as apill, liquid solution, lozenges, topical treatment such as a cream oroil, or any other means of delivery. Hydroxychloroquine preventscytokine release, and cytokine release is what causes anaphylacticflush. Optionally, the hydroxychloroquine is sprayed directly on theusers tongue.

In the method of prevention described above, all, or any combination of,the four antimicrobials disclosed above can be administered in the formof a single small atomizer. The patient sprays the atomizer towards theback of their throat. The spray is administered at least once a day, butpreferably twice a day when coughing starts. Use of the atomizercontinues as directed by the supervising physician.

In a second embodiment, the present invention is directed to a method oftreating an individual with infection or disease with five differentantimicrobials. The five antimicrobials comprise: hydroxychloroquine,azithromycin, vitamin C, vitamin D and zinc. Referring now to FIG. 2,there is shown the method of treatment.

Day 1 following positive test (isolation), the individual takes thefollowing regimen outlined in Table 2:

TABLE 2 Drug AM Dose PM Dose Hydroxychloroquine  200 mg 200 mgAzithromycin  500 mg — Vitamin C 3000 mg — Vitamin D 3000 mg — Zinc  50mg —

On Day 2-Day 5 the individual takes the following regimen outlined inTable 3:

TABLE 3 Drug AM Dose PM Dose Hydroxychloroquine  200 mg 200 mgAzithromycin  250 mg — Vitamin C 3000 mg — Vitamin D 3000 mg — Zinc  50mg —

On Day 6-Day 10, the individual takes the following regimen outlined inTable 4:

TABLE 4 Drug AM Dose PM Dose Hydroxychloroquine  200 mg 200 mg Vitamin C3000 mg — Vitamin D 3000 mg — Zinc  50 mg —

Hydroxychloroquine is administered daily, at 200 mg twice daily for days1-10.

Azithromycin is administered daily, at 500 mg on day 1, and 250 mg days2-5. Optionally, azithromycin can be administered at 250 mg per day for5-10 days with a loading dose of 500 mg×day 1 or simply 250 mg on day 1.Azithromycin may be substituted with doxycycline at a daily dosage rangeof 25 mg to 800 mg, for those unable to take azithromycin.

Vitamin C is administered at 3,000 mg per day ongoing. This 3,000 mg canbe broken up into two 1500 mg doses, one taken in the morning and onetaken at night.

Vitamin D is administered at 3,000 mg per day ongoing. This 3,000 mg canbe broken up into two 1500 mg doses, one taken in the morning and onetaken at night.

Zinc is administered at 50 mg per day ongoing. This 50 mg can be brokenup into two 25 mg doses, one taken in the morning and one taken atnight.

Chloroquine or hydroxychloroquine can be administered in a daily dosagerange of 20 mg to 2,000 mg. The above amounts recited in the tables arenot limiting.

Vitamin C can be administered in a daily dosage range of 250 mg to10,000 mg. The above amounts recited in the tables are not limiting.

Vitamin D can be administered in a daily dosage rage of 1,000 mg to100,000 mg. The above amounts recited in the tables are not limiting.

Zinc can be administered in a daily dosage of 5 mg to 100 mg. The amountof Zinc can be reduced to 25 mg per day if gastrointestinal upsetoccurs.

Concurrently with the above treatment, the individual isself-quarantined per CDC recommendations.

Optionally, for the method of treatment noted above, as the dosages ofthe hydroxychloroquine, vitamin C, vitamin D and zinc remain the samethroughout treatment, all four of those antimicrobials can beadministered in the form of a single small atomizer. The patient spraysthe atomizer towards the back of their throat. The spray is administeredat least once a day, but preferably twice a day when coughing starts.Use of the atomizer continues as directed by the supervising physician.

For all protocols provided in this application, vitamin C dosage canrange from 250 mg to 10,000 mg per day, vitamin D dosage can range from1000 IU (mg) to 100,000 IU (mg) per day, zinc (which can be any form ortype of zinc) dosage can range from 5 mg to 100 mg per day, andhydroxychloroquine dosage can range from 50 mg to 2,000 mg per day for atreatment period of 1 to 10 days treatment. Optionally,hydroxychloroquine can be administered once as single dose. For allprotocols provided in this application, when a dosage range is provided,any dosage amount that is included in that range can be administered.Accordingly, the invention is not limited to the dosage rangesdisclosed, and includes all dosage amounts contained in those ranges.

Optionally, the above protocols can include selenium, copper and othervitamins that are deemed acceptable supplements for vitamin C, vitamin Dor zinc or to counteract the negative depletion of certain vitamins,which is why copper or selenium are typically used.

Treatment can be for one day or consecutive or repeated in 2 weeks, 1month, 6 months or 1 year, or weekly for 6 months.

The above protocols can be used to treat other viruses (not justCOVID-19), including other flu and various respiratory viruses,including more benign coronaviruses and rhinoviruses.

The above protocols can also be used to treat Autism, Parkinson's,Alzheimer's and other neurological diseases.

EXAMPLES Example 1: Hydroxychloroquine, Vitamin C, Vitamin D, and Zincfor Prevention of COVID-19 Infection

Objective:

To determine whether treatment with hydroxychloroquine, vitamin C,vitamin D, and zinc in combination will prevent infection with COVID-19and to assess the safety and tolerability of hydroxychloroquine, vitaminC, vitamin D, and zinc in healthy, high-risk individuals withouthypertension, and no evidence of COVID-19 infection.

Procedure:

Day 1: Prescription of study drugs and home health monitoring equipment.The study drugs are hydroxychloroquine 200 mg twice a day for 1 dayonly, vitamin C 3000 mg per day ongoing, vitamin D 3000 mg per dayongoing, and zinc 50 mg per day ongoing per day. The home healthmonitoring equipment is an electrocardiogram (EKG) which synchs up witha smartphone

Days 2-7: Patient collects the EKG once during this week using the homehealth equipment

Weeks 1-23: Patient provides an assessment of any COVID-19 symptoms andcontinues to collect EKG weekly throughout the remainder of the trial

Week 24: Patient undergoes confirmatory COVID-19 testing which consistsof nasopharyngeal (NP) and oropharyngeal (OP) swabs collected accordingto CDC (Center for Disease Control) protocol. The swabs consist ofsynthetic fiber swabs with plastic shafts. NP swabs are collected byinsertion of a swab into the nostril parallel to the palate. The swab isleft in place a few seconds to allow it to absorb secretions. OP swabsare inserted into the oropharynx parallel to the palate, avoiding thetongue. The swab is left in place a few seconds to allow it to absorbsecretions. The swabs are then immediately placed in sterile tubes with2-3 mL of viral transport media. The tubes are placed in biohazard bagsthen boxes and couriered to the local Public Health Lab.

Table 5 provides a schedule of events for Example 1.

TABLE 5 Screening Weeks Week Assessment (Day 1) Day 3 1-23 24 In-formedconsent and demographics X Review of prior and concomitant medications XEKG at home X X Prescription of Hydroxychloroquine, vitamin C, vitamin XD, and zinc Provision of home health EKG and pulse oximeter X Updatelist of prior and concomitant medications X X X Ask about any adverseevents and any serious adverse X X X events Evaluation of COVID-19symptoms X X COVID-19 testing X Blood draw for future testing X Vitalsin-clinic X Physical exam X

Regarding Table 5: Vitals at home to include EKG and O2Sat, futuretesting will require separate informed consent and could possiblyinclude antibody or cytokine testing, and vitals in-clinic to includeheight, weight, blood pressure (following 5 minutes sitting) pulse,respiratory rate, temperature, and oxygen saturation.

Example 2: Randomized, Double-Blind, Placebo-Controlled Phase IIA Studyof Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Preventionof COVID-19 Infection

Objectives:

Prevention of COVID-19, Lack of COVID-19 symptoms, and assessment ofsafety and tolerability

Procedure:

Screening Period (Days −5 to −1): Prescription of home health monitoringequipment that includes a thermometer, a pregnancy test if applicable,and a daily diary. There are two groups being studied: Arm 1 and Arm 2.

Arm 1 is prescribed the following antimicrobials: hydroxychloroquine 200mg twice a day for 1 day only, vitamin C 3000 IU per day for 12 weeks,vitamin D 3000 IU per day for 12 weeks, and zinc 50 mg per day for 12weeks. The zinc can be reduced to 25 mg if GI upset occurs.

Arm 2 is prescribed the following antimicrobials: Placebo twice a dayfor 1 day only, vitamin C 3000 IU per day for 12 weeks, vitamin D 3000IU per day for 12 weeks, and zinc 50 mg per day for 12 weeks. The zinccan be reduced to 25 mg if GI upset occurs.

Day 1: Patient is called to teach them how to use the diary in the EDC,discuss the medication regimen, and answer any questions they may have.Patient takes pregnancy test if applicable, collects a temperaturereading, completes their diary, and takes the prescribed treatmentregimen. Table 6 outlines the prescribed treatment regimen for Day 1.

TABLE 6 Drug AM Dose PM Dose Hydroxychloroquine (or placebo)  200 mg 200mg Vitamin C 3000 mg — Vitamin D 3000 IU — Zinc  50 mg —

Day 2: Patient collects a temperature reading, completes their diary,and is called on the phone for assessment of any adverse events orserious adverse events, assessment of any COVID-19 symptoms, the list ofprior and concomitant medications is updated, any questions the patienthas are answered, and the patient takes their prescribed treatmentregimen. Table 7 outlines the prescribed treatment regimen for Day 2.

TABLE 7 Drug AM Dose PM Dose Vitamin C 3000 mg — Vitamin D 3000 IU —Zinc  50 mg —

Days 3-10: Patient collects a temperature reading, completes theirdiary, and takes their prescribed treatment regimen. Table 8 outlinesthe prescribed treatment regimen for Days 3-10.

TABLE 8 Drug AM Dose PM Dose Vitamin C 3000 mg — Vitamin D 3000 IU —Zinc  50 mg —

Day 14: The patient is called for instruction on how to collect a nasalswab and package for shipping, assessment COVID-19 symptoms, updatingtheir list of prior and concomitant medications, and answering anyquestions they may have.

Weeks 3-11: The patient is called weekly for assessment of any adverseevents or serious adverse events, assessment of any COVID-19 symptoms,updating their list of prior and concomitant medications, and answeringany questions they may have. The patient takes weekly temperaturereadings, completes their diary, and takes the prescribed treatmentregimen. During Week 4 the patient is reminded to collect a nasal swab.The prescribed treatment regimen for Weeks 3-11 is shown in Table 9.

TABLE 9 Drug AM Dose PM Dose Vitamin C 3000 mg — Vitamin D 3000 IU —Zinc  50 mg —

Week 12: The patient presents to the clinic for evaluation that includesassessment for adverse events and serious adverse events, updating theirlist of prior and concomitant medications, a physical exam, nasal swabcollection and COVID-19 sample collection.

Samples for COVID-19 testing are collected using synthetic swabs withplastic shafts. Nasal swabs are collected and immediately placed into asterile vial with 2-3 mL of viral transport media. The vials are placedinto biohazard bags, boxed up, the box sterilized, and picked up forshipment to the central laboratory. Samples are tested by RT-PCR.

Table 10 presents the schedule of events for Example 2.

TABLE 10 Day Day Day Day Weeks Month Month Month Assessment Screening 12 3-10 14 3-12 1 2 3 Informed Consent & Demographics X Initial Review ofPrior X and Concomitant Medications Medical Records review, X includingbaseline EKG Randomization X Prescription of X Hydroxychloroquine orplacebo, vitamin C, vitamin D, and zinc Provision of daily diary, Xthermometer and pregnancy test Pregnancy Test if applicable XTemperature at home X X X X X X X X Complete daily diary X X X X X X X XHydroxychloroquine 200 mg X Vitamin C 3000 mg X X X X X X X X Vitamin D3000 IU X X X X X X X X Zinc 50 mg^(a) X X X X X X X X Phone/video callto patient^(b) X X X X X X X Update list of prior X X X X X X X X andconcomitant medications Ask about AE and SAE X X X X X X X X Assessmentof COVID-19 symptoms X X X X X X X X Swabs for RT-PCR X X X Vitalsin-clinic^(c) X Physical Exam X

Regarding Table 10: The Zinc may be reduced to 25 mg if GI upset occurs,phone/video calls to the patient occur weekly during Weeks 2-11, andvitals in-clinic include height, weight, blood pressure (following 5minutes sitting) pulse, respiratory rate, temperature, and oxygensaturation.

Statistical Analysis:

The treated patients in this study are compared to the placebo group.Measurements include PCR test results, presence or absence of symptoms,and symptom severity.

The change of these measurements from the end to the baseline (post-pre)are used as the primary outcome, for example, μe=μe1−μe0, where μe1 andμe0 are the outcome of patients from the treatment group at the end andat baseline, respectively.

H₀:Δ≤δ₀ against H_(a):Δ>δ₀ where δ0 is a clinically meaningful thresholdto measure the disease symptoms. In this study, that meaningfulthreshold is calculated as mean change in clinical symptoms as recordedin the diary, from baseline through week 12. Each category in the diaryis assigned a number, 0 for None, 1 for Mild, 2 for Moderate and 3 forsevere. Each category is analyzed independently and as a group.

Categorical variables are summarized by presenting the number (n) andpercent (%) of subjects in each category. All Statistical tests for theanalysis are performed using the p<0.05 level of significance. Allconfidence intervals are one-sided.

Since these are healthcare workers who are exposed to COVID-19 at everyshift, efficacy is determined by RT-PCR testing, as well as the presenceor absence of symptoms as recorded in the patient diary via EDC.

Example 3: Use of Hydroxychloroquine, Azithromycin, Vitamin C, VitaminD, and Zinc to Treat COVID-19 Infection

Objectives: test the efficacy of hydroxychloroquine, azithromycin,vitamin C, vitamin D, and zinc in the treatment of patients withCOVID-19 infection and to assess the safety and tolerability of thistreatment in patients with COVID-19 infection.

Procedure: First, the patient is determined to have COVID-19.

Day 1 following positive test (isolation): The patient takes prescribedregimen outlined in Table 11.

TABLE 11 Drug AM Dose PM Dose Hydroxychloroquine  200 mg 200 mgAzithromycin  500 mg — Vitamin C 3000 mg — Vitamin D 3000 mg — Zinc  50mg —

Day 2-Day 5: The patient takes the prescribed regimen outlined in Table12.

TABLE 12 Drug AM Dose PM Dose Hydroxychloroquine  200 mg 200 mgAzithromycin  250 mg — Vitamin C 3000 mg — Vitamin D 3000 mg — Zinc  50mg —

Day 6-Day 10: The patient takes the prescribed regimen outlined in Table13.

TABLE 13 Drug AM Dose PM Dose Hydroxychloroquine  200 mg 200 mg VitaminC 3000 mg — Vitamin D 3000 mg — Zinc  50 mg —

Follow-Up Period: Month 1 (outpatient only AFTER negative test): vitalsigns are taken that include blood pressure, heart rate, respiratoryrate, oxygen saturation, temperature), the patient is assessed foradverse events and serious adverse events, and swabs for PCR are taken.

Month 3 (outpatient): vital signs are taken that include blood pressure,heart rate, respiratory rate, oxygen saturation, temperature), thepatient is assessed for adverse events and serious adverse events, andswabs for PCR are taken.

Month 6 (outpatient) vital signs are taken that include blood pressure,heart rate, respiratory rate, oxygen saturation, temperature), thepatient is assessed for adverse events and serious adverse events, andswabs for PCR are taken.

Month 9 (outpatient) vital signs are taken that include blood pressure,heart rate, respiratory rate, oxygen saturation, temperature), thepatient is assessed for adverse events and serious adverse events, andswabs for PCR are taken.

Month 12 (outpatient) vital signs are taken that include blood pressure,heart rate, respiratory rate, oxygen saturation, temperature), thepatient is assessed for adverse events and serious adverse events, andswabs for PCR are taken.

COVID-19 sample collection procedure is as follows: nasopharyngeal (NP)and oropharyngeal (OP) swabs are collected according to CDC protocol.The swabs comprise synthetic fiber swabs with plastic shafts. NP swabsare collected by insertion of a swab into the nostril parallel to thepalate. The swab is left in place a few seconds to allow it to absorbsecretions. OP swabs are inserted into the oropharynx parallel to thepalate, avoiding the tongue. The swab is left in place a few seconds toallow it to absorb secretions. NP and OP swabs are immediately placed insterile tubes with 2-3 mL of viral transport media. The tubes are placedin biohazard bags then boxes and couriered to the local Public HealthLab. Table 14 outlines the schedule of events for Example 3.

TABLE 14 Diagnosis and Rx Day Month 1 Month 3 Month 6 Month 9 Month 12Assessment (Day 1) 1→ 7 (±4 d) (±4 d) (±4 d) (±4 d) (+4 d) InformedConsent & Demographics X Confirmation of Positive PCR for X COVID-19Review of Medical Records X Vitals^(a) X X X X X Prescription ofAntimicrobials^(b) X Ask about AE and SAE X X X X X X

Regarding Table 14: Vitals to include height (only at first visit),weight, blood pressure (following 5 minutes sitting) pulse, respiratoryrate, temperature, and oxygen saturation. Dosage to be given as insection 8, below

Table 15 provides a summary of the antimicrobial dosage of Example 3.

TABLE 15 Treatment Method Medication Dose Frequency QuintupleHydroxychloroquine  200 mg BID Therapy Azithromycin 500 mg\Day 1→ Daily250 mg Day 2-5 Vitamin C 3000 mg Daily Vitamin D 5000 mg Daily Zinc  50mg Daily

Example 4: Randomized, Double-Blind, Placebo-Controlled Phase IIA Studyof Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc toTreat COVID-19 Infection

Objectives: Test the efficacy of hydroxychloroquine, azithromycin,vitamin C, vitamin D, and zinc in the treatment of patients withCOVID-19 infection and to assess the safety and tolerability of thistreatment in patients with COVID-19 infection.

Procedure: First, the patient's diagnosis of COVID-19 infection isconfirmed.

Screening Period (Days −3 to −1): Prescription of home health monitoringequipment that includes a thermometer, a pulse oximeter, a pregnancytest if applicable, and a daily diary. There are two groups beingstudied: Arm 1 and Arm 2.

Arm 1 is prescribed the following antimicrobials: Hydroxychloroquine200MG BID for 10 days; Azithromycin 500 mg on day 1, 250 mg day 2-5;Vitamin C 3000 mg for 10 days, then 1500 mg for 20 days; Vitamin D 3000IU for 10 days, then 1500 IU for 20 days; and Zinc 50 mg for 10 days,then 25 mg for 20 days.

Arm 2 is prescribed the following antimicrobials: Placebo forHydroxychloroquine BID for 10 days; Placebo for Azithromycin to be taken2 the on Day 1, then 1 on Days 2-5; Vitamin C 3000 mg for 10 days, then1500 mg for 20 days; Vitamin D 3000 IU for 10 days, then 1500 IU for 20days; and Zinc 50 mg for 10 days, then 25 mg for 20 days. Table 16outlines the prescribed antimicrobials discussed above.

TABLE 16 Treatment Method Medication Dose Frequency QuintupleHydroxychloroquine  200 mg BID Therapy Azithromycin 500 mg\Day 1→ Daily250 mg Day 2-5 Vitamin C 3000 mg Daily Vitamin D 5000 mg Daily Zinc  50mg Daily Placebo Placebo 1 tablet BID Placebo 2 tablets day 1, then 1Daily tablet day 2-5 Vitamin C 3000 mg Daily Vitamin D 3000 IU DailyZinc  50 mg Daily

Treatment Period: Day 1 following positive test (isolation), the patientis video called to ensure they have all study materials and thefollowing is discussed: Use of home health equipment, Subject will takebaseline measurements at this time and record it in the diary, Diary andhow to transmit its contents, Medication dosing, Subject will takepregnancy test if applicable, Subject will use provided equipment tomeasure vital signs such as EKG, Oxygen Saturation, and Temperature. Thepatient takes prescribed regimen outlined in Table 17.

TABLE 17 Drug AM Dose PM Dose Hydroxychloroquine (or Placebo)  200 mg200 mg Azithromycin (or Placebo)  500 mg — Vitamin C 3000 mg — Vitamin D3000 IU — Zinc  50 mg —

Day 2: The patient completes the AM and PM diary entries, the patientuses the provided equipment to measure vital signs such as EKG, Oxygensaturation, and temperature, and the patient takes the prescribedregimen outlined in Table 18.

TABLE 18 Drug AM Dose PM Dose Hydroxychloroquine (for Placebo)  200 mg200 mg Azithromycin (or Placebo)  250 mg — Vitamin C 3000 mg — Vitamin D3000 IU — Zinc  50 mg —

Day 3: The patient is called and asked if they are experiencing anydifficulties with swab collection, whether there have been any adverseevents and/or serious adverse events, the list of prior and concomitantmedications is updated, the patient is asked about symptom resolution orprogression, the patient is instructed on how to collect nasal swabs,and the patient then collects the first nasal swab. The patientcompletes their AM and PM diary entries, and collects their vital signssuch as EKG, oxygen saturation and temperature. The patient takes theprescribed regimen outlined in Table 19.

TABLE 19 Drug AM Dose PM Dose Hydroxychloroquine (or Placebo)  200 mg200 mg Azithromycin (or Placebo)  250 mg — Vitamin C 3000 mg — Vitamin D3000 IU — Zinc  50 mg —

Day 4: The patient completes their AM and PM diary entries, collectstheir vital signs, and takes the prescribed regimen outlined in Table20.

TABLE 20 Drug AM Dose PM Dose Hydroxychloroquine (or Placebo)  200 mg200 mg Azithromycin (for Placebo)  250 mg — Vitamin C 3000 mg — VitaminD 3000 IU — Zinc  50 mg —

Day 5: The patient completes their AM and PM diary entries, collectstheir vital signs, collects a nasal swab, and takes the prescribedregimen outlined in Table 21.

TABLE 21 Drug AM Dose PM Dose Hydroxychloroquine (or Placebo)  200 mg200 mg Azithromycin (or Placebo)  250 mg — Vitamin C 3000 mg — Vitamin D3000 IU — Zinc  50 mg —

Day 6: The patient completes their AM and PM diary entries, collectstheir vital signs, and takes the prescribed regimen outlined in Table22.

Drug AM Dose PM Dose Hydroxychloroquine (or Placebo)  200 mg 200 mgVitamin C 3000 mg — Vitamin D 3000 IU — Zinc  50 mg —

Day 7: The patient is called and asked whether there have been anyadverse events and/or serious adverse events, the list of prior andconcomitant medications is updated, the patient is asked about symptomresolution or progression, and the patient then collects a nasal swab.The patient also completes their AM and PM diary entries and collectstheir vital signs. The patient takes the prescribed regimen outlined inTable 23.

TABLE 23 Drug AM Dose PM Dose Hydroxychloroquine (or Placebo)  200 mg200 mg Vitamin C 3000 mg — Vitamin D 3000 IU — Zinc  50 mg —

Day 8: The patient completes their AM and PM diary entries, collectstheir vital signs, and takes the prescribed regimen outlined in Table24.

TABLE 24 Drug AM Dose PM Dose Hydroxychloroquin (or Placebo)  200 mg 200mg Vitamin C 3000 mg — Vitamin D 3000 IU — Zinc  50 mg —

Day 9: The patient completes their AM and PM diary entries, collectstheir vital signs, and takes the prescribed regimen outlined in Table25.

TABLE 25 Drug AM Dose PM Dose Hydroxychloroquine (or Placebo)  200 mg200 mg Vitamin C 3000 mg — Vitamin D 3000 IU — Zinc  50 mg —

Day 10: The patient is called reminded to decrease dosage of vitamins C,vitamin D, and zinc tomorrow. The patient is asked whether there havebeen any adverse events and/or serious adverse events, the list of priorand concomitant medications is updated, and the patient is asked aboutsymptom resolution or progression. The patient also completes their AMand PM diary entries and collects their vital signs. The patient takesthe prescribed regimen outlined in Table 26.

TABLE 26 Drug AM Dose PM Dose Hydroxychloroquine  200 mg 200 mg orPlacebo) Vitamin C 3000 mg — Vitamin D 3000 IU — Zinc  50 mg —

Day 11 to Day 13: The patient completes their AM and PM diary entriesand takes the prescribed regimen outlined in Table 27.

TABLE 27 Drug AM Dose PM Dose Vitamin C 1500 mg — Vitamin D 1500 IU —Zinc  25 mg —

Day 14: The patient is called and asked whether there have been anyadverse events and/or serious adverse events, the patient is asked aboutsymptom resolution or progression, and the patient then collects a nasalswab. The patient also completes their AM and PM diary entries andcollects their vital signs. The patient takes the prescribed regimenoutlined in Table 28.

TABLE 28 Drug AM Dose PM Dose Vitamin C 1500 mg — Vitamin D I500 IU —Zinc  25 mg —

Day 15 to Day 30: The patient completes their AM and PM diary entriesand takes the prescribed regimen outlined in Table 29.

TABLE 29 Drug AM Dose PM Dose Vitamin C 1500 mg — Vitamin D 1500 IU —Zinc  25 mg —

Follow-Up Period: Month 1 (outpatient only AFTER negative test): Vitalsigns are taken (BP, HR, RR, oxygen saturation, temperature), thepatient is assessed for adverse events and/or serious adverse events,and EKG is administered as well as physical exam and a blood draw forCBC/Complete metabolic panel/C-Reactive Protein. The list of prior andconcomitant medications is updated and a nasal swab is collected.

Month 2 (outpatient): Vital signs are collected (BP, HR, RR, oxygensaturation, temperature) the patient is assessed for adverse eventsand/or serious adverse events, and EKG is administered as well asphysical exam and a blood draw for CBC/Complete metabolicpanel/C-Reactive Protein. The list of prior and concomitant medicationsis updated.

Month 3 (outpatient): Vital signs are taken (BP, HR, RR, oxygensaturation, temperature), the patient is assessed for adverse eventsand/or serious adverse events, and EKG is administered as well asphysical exam and a blood draw for CBC/Complete metabolicpanel/C-Reactive Protein. The list of prior and concomitant medicationsis updated and a nasal swab is collected.

COVID-19 Sample Collection Procedure is the same as that outlined abovein prior Examples. Table 30 outlines the schedule of events for Example4.

TABLE 30 Screening (Da−3 Day Day Day Day Day Day Day Day Day Assessmentto Day−1) 1 2 3 4 5 6 7 8 9 Informed X Consent & Demographics Make listof X X X prior and concomitant medications Confirmation of X PositivePCR for COVID-19 Review of X Medical Records Prescription of XAntimicrobials^(a) Provide home X health equipment^(b) Pregnancytest^(c) X Call Subject at X X X home^(d) Vitals at home^(e) X X X X X XX X X Subject will X X X X X X X X X complete AM/PM diaryHydroxychloroquine X X X X X X X X X 200 mg BID (or placebo AzithromycinX 500 mg (2 tablets) once daily (or placebo) Azithromycin X X X X 250 mg(1 tablet) once daity (or placebo) Vitamin C X X X X X X X X 3000 mg (4capsules) once daily Vitamin D X X X X X X X X 3000 IU (4 capsules) oncedaily Zinc 50 mg (4 X X X X X X X X capsules) once daily Vitamin C 1500mg (2 capsides) once daily Vitamin D 1500 IU (2 capsules) once dailyZinc 25 mg (2 capsules) once daily Ask about AE X X and SAF Vitalsin-clinic^(f) Physical exam EKG in-clinic Swabs for RT- X X X PCRBloodwork^(g) Review list of X X X X X X X X X prior and concomitantmedications Day Day Day Day Day Days Month Month Month Assessment 10 1112 13 14 15-30 1 2 3 Informed Consent & Demographics Make list of X X XX X prior and concomitant medications Confirmation of Positive PCR forCOVID-19 Review of Medical Records Prescription of Antimicrobials^(a)Provide home health equipment^(b) Pregnancy test^(c) Call Subject at X Xhome^(d) Vitals at home^(e) X Subject will X X X X X X complete AM/PMdiary Hydroxychloroquine X 200 mg BID (or placebo Azithromycin 500 mg (2tablets) once daily (or placebo) Azithromycin 250 mg (1 tablet) oncedaity (or placebo) Vitamin C X 3000 mg (4 capsules) once daily Vitamin DX 3000 IU (4 capsules) once daily Zinc 50 mg (4 X capsules) once dailyVitamin C X X X X X 1500 mg (2 capsides) once daily Vitamin D X X X X X1500 IU (2 capsules) once daily Zinc 25 mg (2 X X X X X capsules) oncedaily Ask about AE X X X X X and SAF Vitals in-clinic^(f) X X X Physicalexam X X X EKG in-clinic X X X Swabs for RT- X X X PCR Bloodwork^(g) X XX Review list of X X X X X X X X X prior and concomitant medications

Statistical Analysis: The treated patients in this study are compared tothe placebo group. Measurements include PCR test results, presence orabsence of symptoms, and symptom severity. PCR results will be comparedbetween the groups as positive or negative

In this study, the meaningful threshold is calculated as mean change inclinical symptoms as recorded in the diary, from Day 1 through week 12.Each category in the diary is assigned a number, 0 for None, 1 for Mild,2 for Moderate and 3 for severe. Each category is analyzed independentlyand as a group. Ultimately, efficacy is determined based upon reductionand/or progression of symptomatic days, reduction of symptom severity,as well as analysis of the subject's RT-PCR testing per protocol. Thesedata are compared to an existing database of de-identified Subject data.

The change of these measurements from the end to the baseline (post-pre)are used as the primary outcome, for example, μe=μ_(e1)−μ_(e0), whereμ_(e1) and μ_(e0) are the outcome of Subjects from the treatment groupat the end and at baseline, respectively.

Categorical variables are summarized by presenting the number (n) andpercent (%) of subjects in each category. All Statistical tests for theanalysis are performed using the p<0.05 level of significance. Allconfidence intervals will be one-sided

Sample size was calculated as follows:

$n = \underset{\_}{\log\mspace{14mu}\beta}$ log   ρ

Where

$\underset{\_}{\beta = {{the}\mspace{14mu}{probability}\mspace{14mu}{of}\mspace{14mu} a\mspace{14mu}{Type}\mspace{14mu}{II}\mspace{14mu}{error}}}\rho = {{the}\mspace{14mu}{proportion}\mspace{14mu}{of}\mspace{14mu}{the}\mspace{14mu}{population}\mspace{14mu}{NOT}\mspace{14mu}{affected}}$

The proportion of the population affected by COVID-19 is 0.005 percent,thus 0.995 percent aren't affected

The probability of a type II error is 0.05

Thus:

n = log   0.050 log   0.995 n = 597.647

A sample size of 600 was used.

Example 5: Successful Treatment of COVID-19 Infected Outpatients andProphylaxis of Immediate Associates

Objective: to successfully treat COVID-19 infected outpatients andprophylaxis of immediate associates.

Procedure: Prospective COVID-19 infected individuals were diagnosedusing a Pangea DNA/RNA Shield™ Collection Tube to obtain anasopharyngeal swab and PCR +ve patients were entered into the study.They were immediately commenced on a 10 day course of Hydroxychloroquine(200 mg, twice a day, for 10 days), Azithromycin extended release (500mg on day 1, then 250 mg a day for days 9-10), zinc (50 mg a day fordays 1-10), Vitamin D (3000 IU a day for days 1-10) and Vitamin C (3000mg a day for days 1-10). Some individuals lived alone, otherwiseimmediate partners and family deemed to be most exposed were given aprophylactic which comprised hydroxychloroquine 200 mg twice a day onday 1 only with Zinc, Vitamin C and Vitamin D for given at the samedoses as above for days 1-10.

Results: In 11 families a total of 21 family members were identified tobe PCR COVID-19 positive index cases and were treated with the abovetreatment protocol while 22 exposed associates with negative PCR weregiven the above prophylaxis protocol. This is shown below in Table 31.All 21 index cases were cured of COVID-19 infection as judged by therepeat swab PCR on day 10 and accompanying symptom resolution. None ofthe 22 highly exposed associates developed COVID-19 infection whenretested on day 10 (day 14 in Family 10) in spite of close co-habitationwith the infected index cases. TABLE 31: Results from families received10-day course of daily HCQ (200 mg bd), AZ extended release (500 mg day1, then 250 mg), zinc (50 mg), Vitamin D (3000 IU) and Vitamin C (3000mg)

TABLE 31 After treating with HAZDPAC Cured/ After treating Age (years)-Comorbidities PCR test ZINCD+H family Patientls sex of the of thepositive/negative/ member Family treated patient patients other symptomsprophylaxed  #1 1 23-male Asthma Negative PCR-day Parents overweight, 10diabetes, father with heart disease never got the disease  #2 3 60-maleAsthma All 3 patients cured Mother didn't get (father) the virus 18-male(son) 16-female (daughter)  #3 1 40-female Arvoided intubation Severmultiple Husband did not by leaving hospital symptoms resolved turnpositive at home  #4 2 78-male BCG + COPD, Both cured Daughter, son-in-77-female diabetes, heart law and 2 grandkids disease (heart didn'tcatch the surgery month prior virus Pacemaker, BCG  #5 3 56-male Unableto eat or Started treatment on Wife never got the 27-male drink day 10,Sever disease 24-female Asthma symptoms resolved Cured  #6 1 56-femaleAdmitted to hospital- Husband never got sent home, as two the diseasekids were sick with fever. All recovered with vitamins  #7 1 44-femaleCured, autoimmune Husband and 4 kids issues started never got thedisease  #8 3 52-female Lupus Cured Boyfriend (54 y) 53-male Severeasthma Cured with Diabetes, 19-male Cured son (18) and daughter (16)never got the disease  #9 2 45-female Both cured from Husband and16-male severe symptoms of daughter never got cough and fever thedisease #10 2 44-male Cured from loss of Mother (50 y) never 25-femalesmell, fever, cough got the disease 21-female Cured Partially treatedwith HAZDPAC-slowly turned-ve #11 1 33-female No ICU nurse recoveredBoyfriend never got the disease

Apart from the families a further I11 single infected individuals foundto be swab PCR positive were treated with the above treatment protocol.This is shown below in Table 32. All were also successfully cured of theinfection.

TABLE 32 After treating Age with (years)-sex Comorbidities/symptomsHAZDPAC Patient of the patient of the patients Cured/not #1 44-femaleAsthma Cured (no BCG in childhood) #2 81-male Diarrhea Cured #352-female Fever Cured #4 66-male Valve surgery Cured #5 29-female AsthmaCured (no BCG in childhood) #6 50-female Auto immune thyroiditis, severCured cough and fever #7 43-male Cough, desaturation of oxygen Cured #853-male Diarrhea, cough, fever, Cured desaturation of oxygen #944-female Autoimmune history, fever, Cured increase heart rate #1044-female Pneumothorax discharged from Cured ICU with COVID-19 #1143-male Fever +ve Covid-19 PCR Cured

A further 9 individuals recently closely exposed to Covid-19 infectedpersons were given the prophylaxis protocol outlined above. Theprophylactic worked very well with no exposed person acquiring theinfection. This is shown in Table 33.

TABLE 33 Individual Age (years) & details of the individual Aftertreating with ZINCD+H #1 Mother of 16 year old child who had Prophylaxedand never got the disease COVID-19 #2 24-female, ICU nurse-multipleexposures Prophylaxed and never got the disease #3 47-male, cardiologistexposed to +ve Prophylaxed and never got the disease patients #4 70-malemedical director of a hospital Prophylaxed and never got the disease(exposed to numerous doctors with COVID-19) #5 55-male anaesthesiologist(intubates Prophylaxed and never got the disease COVID-19 patients) #655-ICU nurse(worked on Covid-19 floor) Prophylaxed and never got thedisease #7 40-ICU nurse many Covid-19 patients Prophylaxed and never gotthe disease #8 53-Doctor with pancreatitis Prophylaxed and never got thedisease #9 28-Paramedic-healthy Prophylaxed and never got the disease

Discussion: It was demonstrated that a 10 day combination ofhydroxychloroquine, azithromycin (for 5 days only), zinc with vitamin Dand vitamin C, can result in uniform cure of COVID-19 infection whenused in an outpatient population. The prophylaxis treatment noted abovefor those closely exposed to proven, infected patients can completelyprevent spread of COVID-19. This combination of test-and-treat permitsabolishing of new outbreaks of infection such as a ‘next wave’—byavoiding quarantine to treat the infected and give prophylactics tosurrounding staff and family.

In conclusion, this is an effective anti-Covid-19 therapy as well as aneffective prophylactic combination capable of arresting the spread ofcoronavirus infection throughout the community. This is achieved bytreating the index case and the surrounding associates of the patient asearly as possible after infection is identified and then treating thepeople they live with and close associates.

Example 6: Presence of the SARS-CoV-2 by NGS of Fecal Samples

Objective: In view of the large percentage of SARS-CoV-2 detectible byRT-PCR in stools of infected patients, the objective was to identify thepresence of the SARS-CoV-2 by NGS of fecal samples from symptomaticstudy participants positive for SARS-CoV-2 by nasopharyngeal sampleRT-PCR, in addition to asymptomatic individuals (with or without priornasopharyngeal sample RT-PCR). The objective was also to execute wholegenome analysis to characterize SARS-CoV-2 mutational variations toidentify potentially significant nucleotide changes.

Procedure: Study participants (n=14) underwent testing for SARS-CoV-2from fecal samples by whole genome enrichment NGS. Following fecalcollection (Zymo Research Shield Fecal Collection Tubes), RNA wasextracted (Qiagen Allprep Power Viral Kit), reverse transcribed (NewEngland Biolabs NEBNext 1st and 2nd Strand Synthesis Modules), libraryprepped (Illumina Nextera Flex for Enrichment), enriched (IluminaRespiratory Virus Oligo Panel), and sequenced on Illumina's NextSeq 550System. Sequences were then mapped to the SARS-CoV-2 Wuhan-Hu-1(MN90847.3) complete genome utilizing One Codex's SARS-CoV-2bioinformatics analysis pipeline. SARS-CoV-2 positive samples werefurther analyzed for mutational variants that differed from thereference genome. Of the 14 study participants, 12 also had theirnasopharyngeal swabs tested for SARS-CoV-2 by RT-PCR.

Results: The results from patients that had their stool samples testedby whole genome enrichment NGS, and their nasopharyngeal swabs tested byRT-PCR for the presence of SARS-CoV-2 were evaluated. Of the 14 studyparticipants, ten were symptomatic and tested positive for SARS-CoV-2 byRT-PCR, two asymptomatic individuals tested negative, and two otherasymptomatic individuals did not undergo RT-PCR testing (Table 34).Patients 5 and 7, which tested positive by RT-PCR from nasopharyngealswabs, were treated with the protocol from Example 5 above(Hydroxychloroquine, Azithromycin, vitamin C, vitamin D, and zinc for 10days prior to fecal collection). Similarly, after positivenasopharyngeal swab, patient 13 was treated with vitamin C, vitamin D,and zinc for 10 days (the same protocol as noted above in Example 5)before fecal collection. The concordance of SARS-CoV-2 detection byenrichment NGS from stools among positive non-treated patients tested byRT-PCR nasopharyngeal analysis was 100n (7/7). Patient 8, who did notundergo nasopharyngeal analysis, tested positive for SARS-CoV-2 by NGS.The three patients (5, 7, 13) that received treatment prior to providingfecal samples, all tested negative by NGS. Asymptomatic patients 2 and9, who tested negative by nasopharyngeal swab, were also negative byNGS, as was asymptomatic patient 14. Table 34 outlines the symptoms andSARS-CoV-2 testing results.

TABLE 34 Nasopharyngeal Swab (RT- Fecal Patient Sample ID Symptoms PCR)Treated (NGS) Location Patient 1 febrile, diarrhea, anosmia, O2 sat.<90% + no + PA Patient 3 febrile, diarrhea, O2 sat. <90% + no + CAPatient 4 febrile, diarrhea, anosmia, O2 sat. <90% + no + AZ Patient 6febrile, cough, anosmia + no + AZ Patient 8 none n/a no + CA Patient 10febrile, cough, headache + no + GA Patient 11 febrile, cough, headache +no + GA Patient 12 febrile, cough + no + GA Patient 5 febrile, cough +yes − CA Patient 7 febrile, cough + yes − GA Patient 13 febrile, cough −yes − GA Patient 2 none − no − CA Patient 9 none + no − CA Patient 14none n/a no − CA

All fecal samples analyzed by enrichment NGS from positive patients byRT-PCR, achieved 100% genome coverage of SARS-CoV-2 except for patient 3which had 45%, and patient 10 which had 93% coverage. Table 35 outlinesthe enrichment NGS metrics.

TABLE 35 Genome #Variants Mapped Mean Sample ID Coverage (over 10x)Reads Depth Patient 1 100% 11 465645 1129.8x Patient 3 45% 11 5984 31.7xPatient 4 100% 9 131582 318.6x Patient 6 100% 10 793603 11924.6x Patient8 100% 10 496852 1206.7 Patient 10 93% 9 5929 15.6x Patient 11 100% 101270734 3075.3x Patient 12 100% 10 38256 92.7x

The total number of SARS-CoV-2 mapped reads for patients 1, 3, 4, 6, 8,10, 11, and 12 were 465645, 5984, 131582, 793603, 496852, 5929, 1270734,and 38256 respectively. The mean read depths of SARS-CoV-2 for patients1, 3, 4, 6, 8, 10, 11, and 12 were 1129.8×, 31.7×, 318.6×, 1924.6×,1206.7×, 15.5×, 3075.3×, and 92.7×, and respectively. The read depths atspecific coordinates along the SARS-CoV-2 genome for each patient arecaptured in FIGS. 3A-3H. Whole genome alignment of SARS-CoV-2 inpatients 1, 3, 4, 6, 8, 10, 11, and 12 (respectively) as identified byOne Codex's SARS-CoV-2 analysis pipeline. The x-axis depicts the genomiccoordinates as aligned to the MN908947.3 reference genome, and they-axis represents the read depth at specific loci.

Following alignment and mapping of SARS-CoV-2, patient genomes werecompared to the Wuhan-Hu-1 (MN90847.3) SARS-CoV-2 reference genome viaOne Codex's bioinformatics pipeline to identify mutational variations.This analysis identified nucleotide variants at positions nt241 (C→T)and nt23403 (A→G) across all positive patients, and variants atpositions nt3037 (C→T) and nt25563 (G→T) in seven of the eight patients(Table 3). Interestingly, patients 8, 11, and 12 harbored the same setof variants, as did patients 4 and 6 (who were kindred). Unique variantsnot identified in any of the other individuals were detected in patients1, 3, 6, and 10, with patient 3 harboring the most distinct SARS-CoV-2genome with eight unique variants, followed by patient 1 with seven.Collectively, there were thirty-three different mutations among thepatients in which SARS-CoV-2 was detected by whole genome enrichmentNGS. Table 36 outlines the SARS-CoV-2 genomic positions, variantchanges, and frequencies across the positive patient cohort.

TABLE 36 Patient Patient Patient Patient Patient Patient Patient PatientRegion (ORF) Position Variant 1 3 4 6 8 10 11 12 5′-UTR 241 C → T 100%100% 100% 100% 100% 100% 100% 100% 1a 833 T → C x x x x 100% x 100% 100%1a 1059 C → T x x 100% 100%  99% 100% 100% 100% 1a 1758 C → T x x 100%100% x x x x 1a 1973 C → T x x x  87% x x x x 1a 3037 C → T 100% X 100%100% 100% 100% 100% 100% 1a 3078 C → T x  89% x x x x x x 1a 4866 G → T 75% x x x x x x x 1a 6720 C → T  93% x x x x x x x 1a 8102 G → T x 100%x x x x x x 1a 9401 T → C x x x x x  64% x x 1a 9403 T → A x x x x x 64% x x 1a 10870 G → T x x 100% 100% x x x x 1a 11123 G → A x x 100%100% x x x x 1b 14408 C → T 100% x 100% 100% 100% x 100% 100% 1b 14877 C→ T x 100% x x x x x x 1b 16616 C → T x x x x 100% x 100% 100% 1b 16848C → T 100% x x x x x x x 1b 18652 C → A x x x x x 83% x x 1b 19989 T → Gx 100% x x x x x x Spike 21576 T → G x  83% x x x x x x Spike 23264 G →A x  75% x x x x x x Spike 23403 A → G 100% 100% 100% 100% 100% 100%100% 100% Spike 23603 C → T  82% x x x x x x x 3a 25563 G → T x 100%100% 100% 100% 100% 100% 100% 3a 25976 C → A x x x x 100% x 100% 100% 827964 C → T x x x x 100% x 100% 100% Nucleoprotein 28881 G → A 100% x xx x x x x Nucleoprotein 28882 G → A 100% x x x x x x x Nucleoprotein28883 G → C 100% x x x x x x x Nucleoprotein 28997 C → T x 100% x x x xx x Nucleoprotein 29019 A → T x 100% x x x x x x Nucleoprotein 29364 C →G x x x x x  85% x x

Discussion: Although previous studies have identified SARS-CoV-2 infecal collections by RT-PCR, this study was able to report whole genomesequencing (WGS) of SARS-CoV-2 from stool samples. SARS-CoV-2 wasidentified in patients that tested positive by nasopharyngeal swabRT-PCR analysis and unique genomes in 62.5%/o of the NGS positivepatients was observed. The overall homology among the genomes was high(99.97%/), with variations identified in the ORF regions 1a, 1b, S, 3a,8, and N. Of particular interest, was the adenine to guanine change inthe S protein at position nt23403 which converts aspartic acid toglycine (D→G).

Conclusion: Next generation sequencing identified the SARS-CoV-2 wholegenome sequence in 100% of patients with positive nasopharyngeal RT-PCRand did not detect it in treated patients, or those with negativert-PCR. These results highlight the importance of metagenomic analysisof the SARS-CoV-2 viral genome.

Example 7: Randomized, Double-Blind, Placebo-Controlled Phase IIA Studyof Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Preventionof COVID-19 Infection

Objectives: Prevention of COVID-19, Lack of COVID-19 symptoms, andassessment of safety and tolerability

Procedure: Screening Period (Days −7 to −1): Prescription of home healthmonitoring equipment that includes a thermometer, a pregnancy test ifapplicable, and a daily diary. There are two groups being studied: Arm 1and Arm 2.

Arm 1 is prescribed the following antimicrobials: hydroxychloroquine 200mg twice a day for 1 day only, vitamin C 3000 IU per day for 12 weeks,vitamin D 3000 IU per day for 12 weeks, and zinc 50 mg per day for 12weeks. The zinc can be reduced to 25 mg if GI upset occurs. Thehydroxychloroquine is to be taken first thing in the morning as soon assubject has eaten and again right before bed, and must be separated fromvitamin dose by at least 2 hours.

Arm 2 is prescribed the following antimicrobials: Placebo twice a dayfor 1 day only, vitamin C 3000 IU per day for 12 weeks, vitamin D 3000IU per day for 12 weeks, and zinc 50 mg per day for 12 weeks. The zinccan be reduced to 25 mg if GI upset occurs.

Day 1: Patient is called to teach them how to use the diary in the EDC,discuss the medication regimen, and answer any questions they may have.Patient takes pregnancy test if applicable, collects a temperaturereading, completes their diary, and takes the prescribed treatmentregimen. Table 37 outlines the prescribed treatment regimen for Day 1.

TABLE 37 Drug AM Dose PM Dose Hydroxychloroquine  200 mg  200 mg (orplacebo) Vitamin C 1500 mg 1500 mg Vitamin D 1500 IU 1500 IU Zinc  25 mg 25 mg

Day 2: Patient collects a temperature reading, completes their diary,and is called on the phone for assessment of any adverse events orserious adverse events, assessment of any COVID-19 symptoms, the list ofprior and concomitant medications is updated, any questions the patienthas are answered, and the patient takes their prescribed treatmentregimen. Table 38 outlines the prescribed treatment regimen for Day 2.

TABLE 38 Drug AM Dose PM Dose Vitamin C 1500 mg 1500 mg Vitamin D 1500IU 1500 IU Zinc  25 mg  25 mg

Days 3-10: Patient collects a temperature reading, completes theirdiary, and takes their prescribed treatment regimen. Table 8 outlinesthe prescribed treatment regimen for Days 3-10.

TABLE 8 Drug AM Dose PM Dose Vitamin C 1500 mg 1500 mg Vitamin D 1500 IU1500 IU Zinc  25 mg  25 mg

Day 14: The patient is called for instruction on how to collect a nasalswab and package for shipping, assessment COVID-19 symptoms, updatingtheir list of prior and concomitant medications, and answering anyquestions they may have.

Week 3: The patient is called for assessment of any adverse events orserious adverse events, assessment of any COVID-19 symptoms, updatingtheir list of prior and concomitant medications, and answering anyquestions they may have. The patient takes a temperature reading,completes their diary, and takes the prescribed treatment regimen.

Table 39 outlines the treatment regime for week 3.

TABLE 39 Drug AM Dose PM Dose Vitamin C 1500 mg 1500 mg Vitamin D 1500IU 1500 IU Zinc  25 mg  25 mg

Week 4: The patient is called for assessment of any adverse events orserious adverse events, assessment of any COVID-19 symptoms, updatingtheir list of prior and concomitant medications, and answering anyquestions they may have. The patient takes a temperature reading,completes their diary, and takes the prescribed treatment regimen. Thepatient also collects a nasal swab.

Table 40 outlines the treatment regime for week 4.

TABLE 40 Drug AM Dose PM Dose Vitamin C 1500 mg 1500 mg Vitamin D 1500IU 1500 IU Zinc  25 mg  25 mg

Weeks 5-11: The patient is called weekly for assessment of any adverseevents or serious adverse events, assessment of any COVID-19 symptoms,updating their list of prior and concomitant medications, and answeringany questions they may have. The patient takes a weekly temperaturereading, completes their diary, and takes the prescribed treatmentregimen.

Table 41 outlines the treatment regime for weeks 5-11.

TABLE 41 Drug AM Dose PM Dose Vitamin C 1500 mg 1500 mg Vitamin D 1500IU 1500 IU Zinc  25 mg  25 mg

Week 12: The patient presents to the clinic (or video conference) forevaluation that includes assessment for adverse events and seriousadverse events, updating their list of prior and concomitantmedications, a physical exam, nasal swab collection and COVID-19 samplecollection.

Samples for COVID-19 testing are collected using synthetic swabs withplastic shafts. Nasal swabs are collected and immediately placed into asterile vial with 2-3 mL of viral transport media. The vials are placedinto biohazard bags, boxed up, the box sterilized, and picked up forshipment to the central laboratory. Samples are tested by RT-PCR.

Table 42 presents the schedule of events for Example 7.

TABLE 42 Screening (Day −7 Day Day Day Day Week Week 4/ Week Assessmentto Day 1) 1 2 3-10 14 3 Month 1 5 Informed Consent & Demographics XInitial Review of Prior and Concomitant Medications X Medical Recordsreview, including baseline EKG X Randomization X Prescription ofHydroxychloroquine or placebo, vitamin X C, vitamin D, and zincProvision of daily diary, thermometer and pregnancy test X PregnancyTest if applicable X Temperature at home X X X X X X X Complete dailydiary X X X X X X X Hydroxychloroquine 200 mg X Vitamin C 3000 mg X X XX X X X Vitamin D 3000 IU X X X X X X X Zinc 50 mg^(a) X X X X X X XPhone/video call to patient^(b) X X X X X X X Update list of prior andconcomitant medications X X X X X X X Ask about AE and SAE X X X X X X XAssessment of COVID-19 symptoms X X X X X X X Swabs for RT-PCR X X XVitals in-clinic^(c) Physical Exam Week Week Week 8/ Week Week Week Week12/ Assessment 6 7 Month 2 9 10 11 Month 3 Informed Consent &Demographics Initial Review of Prior and Concomitant Medications MedicalRecords review, including baseline EKG Randomization Prescription ofHydroxychloroquine or placebo, vitamin C, vitamin D, and zinc Provisionof daily diary, thermometer and pregnancy test Pregnancy Test ifapplicable Temperature at home X X X X X X X Complete daily diary X X XX X X X Hydroxychloroquine 200 mg Vitamin C 3000 mg X X X X X X XVitamin D 3000 IU X X X X X X X Zinc 50 mg^(a) X X X X X X X Phone/videocall to patient^(b) X X X X X X Update list of prior and concomitantmedications X X X X X X X Ask about AE and SAE X X X X X X X Assessmentof COVID-19 symptoms X X X X X X X Swabs for RT-PCR X Vitalsin-clinic^(c) X Physical Exam X

Regarding Table 42: The Zinc may be reduced to 25 mg if GI upset occurs,phone/video calls to the patient occur weekly during Weeks 2-11, andvitals in-clinic include height, weight, blood pressure (following 5minutes sitting) pulse, respiratory rate, temperature, and oxygensaturation.

Statistical Analysis: The treated patients in this study are compared tothe placebo group. Measurements include PCR test results, presence orabsence of symptoms, and symptom severity.

The change of these measurements from the end to the baseline (post-pre)are used as the primary outcome, for example, μe=μe1−μe0, where μe1 andμe0 are the outcome of patients from the treatment group at the end andat baseline, respectively.

H₀: Δ≤₀ against H_(a):Δ>δ₀ where δ0 is a clinically meaningful thresholdto measure the disease symptoms. In this study, that meaningfulthreshold is calculated as mean change in clinical symptoms as recordedin the diary, from baseline through week 12. Each category in the diaryis assigned a number, 0 for None, 1 for Mild, 2 for Moderate and 3 forsevere. Each category is analyzed independently and as a group.

Categorical variables are summarized by presenting the number (n) andpercent (%) of subjects in each category. All Statistical tests for theanalysis are performed using the p<0.05 level of significance. Allconfidence intervals are one-sided.

Since these are healthcare workers who are exposed to COVID-19 at everyshift, efficacy is determined by RT-PCR testing, as well as the presenceor absence of symptoms as recorded in the patient diary via EDC.

Having thus described the invention, it should be apparent that numerousstructural modifications and adaptations may be resorted to withoutdeparting from the scope and fair meaning of the instant invention asset forth herein above and described herein below by the claims.

While particular forms of the invention have been illustrated anddescribed, it will also be apparent to those skilled in the art thatvarious modifications can be made without departing from the spirit andscope of the invention.

Although the present invention has been described in considerable detailwith reference to certain preferred embodiments, other embodiments arepossible. The forgoing description is not intended to be exhaustive orto limit the invention to the precise form disclosed. Many modificationsand variations are possible in light of the above teaching. The stepsdisclosed for the present methods, for example, are not intended to belimiting nor are they intended to indicate that each step is necessarilyessential to the method, but instead are exemplary steps only.Therefore, the scope of the appended claims should not be limited to thedescription of preferred embodiments/methods contained in thisdisclosure. All references cited herein are incorporated by reference.Insofar as the description above and the accompanying drawings discloseany additional subject matter that is not within the scope of the claimsbelow, the inventions are not dedicated to the public and the right tofile one or more applications to claim such additional inventions isreserved.

1. (canceled)
 2. A method of preventing COVID-19 infection, the methodcomprising the steps of: a) providing an individual that is not infectedwith COVID-19; b) administering, on day 1: i) two doses of 200 mg ofhydroxychloroquine; ii) one dose of 3,000 mg of vitamin C; iii) one doseof 3,000 IU of vitamin D; and iv) one dose of 50 mg of zinc; and c)administering on day 2: v) one dose of 3,000 mg of vitamin C; vi) onedose of 3,000 IU of vitamin D; and vii) one dose of 50 mg of zinc; d)monitoring the individuals condition over a pre-determined amount oftime to determine the individual does not become infected with COVID-19.3. The method of claim 2, wherein the antimicrobials are administeredorally in step b) in the form of an aerosolized spray.
 4. The method ofclaim 2, wherein the two doses of hydroxychloroquine are administered asa single daily dose. 5.-7. (canceled)
 8. The method of claim 2, whereinthe step of administering on day 2 is performed for two weeks. 9.-19.(canceled)
 20. The method of claim 2, wherein steps b) and c) areperformed weekly for two weeks.
 21. The method of claim 2, wherein stepsb) and c) are performed weekly for three weeks.
 22. The method of claim2, wherein steps b) and c) are performed weekly for four weeks.
 23. Themethod of claim 2, wherein steps b) and c) are performed weekly for fiveweeks.
 24. The method of claim 2, wherein steps b) and c) are performedweekly for six weeks. 25.-29. (canceled)